Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials

M. Clarke; A. S. Coates; S. C. Darby; C. Davies; R. D. Gelber; Jon Godwin; A. Goldhirsch; R. Gray

doi:10.1016/S0140-6736(08)60069-0

Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials

M. Clarke, A. S. Coates, S. C. Darby, C. Davies, R. D. Gelber, Jon Godwin, A. Goldhirsch, R. Gray

Research output: Contribution to journal › Article

Abstract

The long-term effects of adjuvant polychemotherapy regimens in oestrogen-receptor-poor (ER-poor) breast cancer, and the extent to which these effects are modified by age or tamoxifen use, can be assessed by an updated meta-analysis of individual patient data from randomised trials. Collaborative meta-analyses of individual patient data for about 6000 women with ER-poor breast cancer in 46 trials of polychemotherapy versus not (non-taxane-based polychemotherapy, typically about six cycles; trial start dates 1975–96, median 1984) and about 14 000 women with ER-poor breast cancer in 50 trials of tamoxifen versus not (some trials in the presence and some in the absence of polychemotherapy; trial start dates 1972–93, median 1982).

Original language	English
Pages (from-to)	29-40
Number of pages	12
Journal	Lancet
Volume	371
Issue number	9606
DOIs	https://doi.org/10.1016/S0140-6736(08)60069-0
Publication status	Published - 1 Jan 2008

Fingerprint

Keywords

breast cancer
oestrogen receptor
adjuvant therapy
clinical trials
chemotherapy

Cite this

Clarke, M., Coates, A. S., Darby, S. C., Davies, C., Gelber, R. D., Godwin, J., Goldhirsch, A., & Gray, R. (2008). Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet, 371(9606), 29-40. https://doi.org/10.1016/S0140-6736(08)60069-0

@article{a7d7251e0a014db28dd7e8d16dfde088,

title = "Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials",

abstract = "The long-term effects of adjuvant polychemotherapy regimens in oestrogen-receptor-poor (ER-poor) breast cancer, and the extent to which these effects are modified by age or tamoxifen use, can be assessed by an updated meta-analysis of individual patient data from randomised trials. Collaborative meta-analyses of individual patient data for about 6000 women with ER-poor breast cancer in 46 trials of polychemotherapy versus not (non-taxane-based polychemotherapy, typically about six cycles; trial start dates 1975–96, median 1984) and about 14 000 women with ER-poor breast cancer in 50 trials of tamoxifen versus not (some trials in the presence and some in the absence of polychemotherapy; trial start dates 1972–93, median 1982).",

keywords = "breast cancer, oestrogen receptor, adjuvant therapy, clinical trials, chemotherapy",

author = "M. Clarke and Coates, {A. S.} and Darby, {S. C.} and C. Davies and Gelber, {R. D.} and Jon Godwin and A. Goldhirsch and R. Gray",

note = "<p>Originally published in: The Lancet (2008), 371 (9609), pp.29-40.</p>",

year = "2008",

month = jan

day = "1",

doi = "10.1016/S0140-6736(08)60069-0",

language = "English",

volume = "371",

pages = "29--40",

journal = "Lancet",

issn = "0140-6736",

publisher = "Elsevier Ltd",

number = "9606",

}

TY - JOUR

T1 - Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials

AU - Clarke, M.

AU - Coates, A. S.

AU - Darby, S. C.

AU - Davies, C.

AU - Gelber, R. D.

AU - Godwin, Jon

AU - Goldhirsch, A.

AU - Gray, R.

N1 - <p>Originally published in: The Lancet (2008), 371 (9609), pp.29-40.</p>

PY - 2008/1/1

Y1 - 2008/1/1

N2 - The long-term effects of adjuvant polychemotherapy regimens in oestrogen-receptor-poor (ER-poor) breast cancer, and the extent to which these effects are modified by age or tamoxifen use, can be assessed by an updated meta-analysis of individual patient data from randomised trials. Collaborative meta-analyses of individual patient data for about 6000 women with ER-poor breast cancer in 46 trials of polychemotherapy versus not (non-taxane-based polychemotherapy, typically about six cycles; trial start dates 1975–96, median 1984) and about 14 000 women with ER-poor breast cancer in 50 trials of tamoxifen versus not (some trials in the presence and some in the absence of polychemotherapy; trial start dates 1972–93, median 1982).

AB - The long-term effects of adjuvant polychemotherapy regimens in oestrogen-receptor-poor (ER-poor) breast cancer, and the extent to which these effects are modified by age or tamoxifen use, can be assessed by an updated meta-analysis of individual patient data from randomised trials. Collaborative meta-analyses of individual patient data for about 6000 women with ER-poor breast cancer in 46 trials of polychemotherapy versus not (non-taxane-based polychemotherapy, typically about six cycles; trial start dates 1975–96, median 1984) and about 14 000 women with ER-poor breast cancer in 50 trials of tamoxifen versus not (some trials in the presence and some in the absence of polychemotherapy; trial start dates 1972–93, median 1982).

KW - breast cancer

KW - oestrogen receptor

KW - adjuvant therapy

KW - clinical trials

KW - chemotherapy

UR - http://www.scopus.com/inward/record.url?eid=2-s2.0-37549055451&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(08)60069-0

DO - 10.1016/S0140-6736(08)60069-0

M3 - Article

VL - 371

SP - 29

EP - 40

JO - Lancet

JF - Lancet

SN - 0140-6736

IS - 9606

ER -

Documents and Links

10.1016/S0140-6736(08)60069-0